chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tongue and throat swelling, followed by dizziness and slight itchiness. Was monitored by RN and symptoms subsided after about 30 minutes with no treatment. Vital signs were normal. Blood glucose check was normal.
Shortly after receiving the vaccine(5-10 min) my mouth and throat started tingling. I took 25 mg of Benadryl ( fast melts).  The tingling lasted 1-1.5 hours and then resolved.
10/28/04: 10 days after vaccine : developed red area adjacent to injection site. Not hot or tender or raised. +/- 0.5 inch diameter. 10/29/04: area of redness widening to +/- 1 inch diameter. Irregular raised surface. No vesicles. Non-tender, indurated and firm. Temperature 100.6 degrees at home. Treated with Keflex IV case early infection.
This case was received from a consumer on 17 October 2007. A female patient, date of birth 09 June 1940, received five injections of Imovax (lot number unknown) and one injection of RIG (lot number unknown) following bat exposure. RIG was given on 27 August 1997. Imovax injections were given on 27 August 1997, 30 August 1997, 03 September 1997, 10 September 1997, and 24 September 1997. In 2001, the patient was found to have an adrenal tumor, which was removed and determined to be benign. In 2007, the patient was diagnosed with "post. subcapsular cataract and nuclear oil droplet cataract". Medical history included spring and fall allergies, increased blood pressure, and underactive thyroid. At the time of vaccination, the patient was taking Synthroid, Avapro, and Cardizem CD concomitantly. Outcome was not reported.
The pt experienced idiopathic thrombocytopenic purpura. This started on 3/6/00 and the pt was first seen on 3/13/00. No treatment was given.
This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 86-year-old male patient who received SHINGRIX. Concomitant products included Metformin, Rosuvastatin, amiodarone, CENTRUM Vitamins, ELIQUIS, JANUVIA, Insulin (Long Acting), Insulin Short Acting and metoprolol. On 10th April 2018, the patient received the 1st dose of SHINGRIX. On 13th April 2018, 3 days after receiving SHINGRIX, the patient experienced diarrhea. In April 2018, the patient experienced pain in arm. In April 2018, the outcome of the pain in arm and diarrhea were recovered/resolved. It was unknown if the reporter considered the pain in arm and diarrhea to be related to SHINGRIX. Additional details were provided as follows: The daughter reported that her father (patient) received the SHINGRIX vaccine and experienced a sore arm. The patient received SHINGRIX in the unknown arm.
Starting at 9:00 pm on 02/03/21-fatigue and headache At 2:30 am on 02/04/21-experienced previous listed symptoms and body aches, chills, light headedness
Pericarditis Patient is current on Ibuprofen and Colchicine as per Cardiology recommendation  Awaiting Echocardiogram  clinically improved Patient presented with left sided chest pain, improved by sitting forward. Pleuritic-type chest pain
Tingling and numbness on the left side especially the fingers and toes(1/13/21). Burning sensation (1/13/21)on the left armpit and later on axillary lymph edema(1/14/21)and heaviness of the arm.  Itching and joint pain on left arm. Muscle pain ,cold and injection site pain since the evening of 1/12/21.
No adverse symptoms reported; inadvertently administered an expired dose of PROQUAD; This spontaneous report was received from a registered nurse and refers to a 4-year-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. On 10-FEB-2020, the patient was inadvertently vaccinated with an expired dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, recombinant human albumin (rHA) (lot # R022571, expiration date 04-FEB-2020) (route of administration was not reported) for prophylaxis, diluted in sterile diluent (dose, lot # and expiration date were not reported).  No adverse symptoms were reported.
Patient experienced heaviness and pain, and hardness in arm. Later in night she got worse pain and a pink swelling from shoulder to elbow.
pt recvd vax 2JAN94 & c/o soreness in lt arm drainage of white liquid, nausea & h/a for past 2 days; treated @ home w/warm shower & triple ATB ointment;
Hours after the second dose of the Phifzer vaccine, my daughter woke up the following day to these symptoms that wrote down on 9/14: Today she came home sick. She had a fever, fatigue, back ache, numbness in her leg and felt like her chest was tight. We took her blood pressure and on the Watch it said A fib several times. It was up to like 122 when she was perfectly still. I took her to the ER. The saw a Long QT on her EKG but told us to follow up with our doctor. We found out that patient?s liver and thyroid levels were abnormal on 10/3. On 10/19 her CT results came back  with pulmonary embolisms on both upper lobes on the branch arteries. she was hospitalized for 2 days and has been on blood thinners ever since. All blood tests for blood disorders have come back negative.
COVID-19 symptoms started evening of 06/25/2022; tested positive on 06/28/2022. My symptoms were severe congestion, slight cough, fever, and chills. Fever and chills lasted for 48 hours, other symptoms lasted 5 days. I took over the counter Tylenol and Nyquil to help sleep. The Doctor did prescribe Paxlovid but my pharmacy didn't get it. I did have telemedicine visit with PCP.
If this is normal due to her steroid injections and causing an interaction with the vaccine; Sweating; She has had hot sensations in her back where she had trigger point injection shots/became very warm; This is a spontaneous report from a contactable consumer or other non hcp.     A 41-years-old female patient received bnt162b2 (BNT162B2 solution for injection), dose 2 via an unspecified route of administration, administered in Arm Left on 28Jan2021 12:30 (Batch/Lot Number was EL9264) as 2ND DOSE, single for an unspecified indication. Caller stated she got her second dose today of the vaccine, caller states she got trigger point cortisone shots last week, did not mention it to the people administering the vaccine, states after she got the vaccine, the sites where she got the injections for her trigger points became very warm, she states at one point she began sweating. States she got her second dose of the Covid vaccine today, 28Jan2021 at 12:30PM in her left arm, states the injections for the trigger spots are on the same side as the vaccine in her arm and shoulder, states it feels like her whole back is warm now, states it has improved some since about 30 minutes after the vaccine was administered. Caller clarifies the medication she received last week in her trigger areas in shoulder and back is called Bupivacaine, no further information provided. Medical history included none, Concomitant medication(s) included bupivacaine taken for an unspecified indication, start and stop date were not reported. On 28Jan2021, the patient experienced she has had hot sensations in her back where she had trigger point injection shots/became very warm with outcome of recovering if this is normal due to her steroid injections and causing an interaction with the vaccine, sweating with outcome of unknown.   Follow-up (28Jan2021): This is a Follow-up spontaneous report from a contactable consumer. This consumer (patient) reported, Information was added.  Follow-up attempts are completed. No further information is expected.
This case was reported by a healthcare professional (nurse) and described the occurrence of wrong vaccine administered in a 4-year-old subject of unspecified gender who was vaccinated with BOOSTRIX, (GlaxoSmithKline). Concurrent vaccination included MMR vaccine (non-GSK); Merck; given on 6 December 2013; Varicella virus vaccine (non-GSK); Merck; given on 6 December 2013. On 6 December 2013 the subject received a dose of BOOSTRIX (.5 ml, intramuscular, left thigh) and experienced wrong vaccine administered, inappropriate age at vaccine administration and vaccine administered at inappropriate site. The nurse reported that the 4-year 5-month old subject received BOOSTRIX instead of KINRIX on 06 December 2013. The nurse stated that because "KINRIX and BOOSTRIX look so similar, someone had placed a BOOSTRIX in with the BOOSTRIX". She reported no adverse events occurred as the child subject did go home. BOOSTRIX is indicated for use in 10 years of age or older and injected into the deltoid muscle of the upper arm. Additional information received on 09 December 2013 via healthcare professional. The healthcare professional reported the 4-year-old subject was vaccinated on 06 December 2013 with a dose of BOOSTRIX (unknown) as the 5th dose in the series. On 7 December 2013, 1 day after vaccination with BOOSTRIX, the subject experienced injection site soreness. The soreness was described as a mild injection site reaction. The immunization series was not delayed or discontinued. On 8 December 2013, the injection site soreness was resolved. The healthcare professional considered the injection site soreness was probably related to vaccination with BOOSTRIX. Discrepant information regarding the sex of the subject was initially it reported as a female and follow-up indicated the subject was a male. Follow-up information was received on 15 January 2014 via healthcare professional who reported the subject was seen at a well child physical examination. The healthcare professional clarified that the subject was a 4-year-old female who developed an additional event of a quarter size redness. The events occurred on 08 December 2013 and resolved on 10 December 2013. The reporting healthcare professional associated the events with BOOSTRIX and were not considered serious. The healthcare professional attributed the events to erroneous administration in which a 4-year old subject received BOOSTRIX instead of appropriate Dtap vaccine. The subject had not received BOOSTRIX before. No action was taken with BOOSTRIX, series was not discontinued. The subject was administered the correct Dtap on 09 December 2013. At the time of the report the injection site soreness and injection site redness were resolved.
Rash was going away; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of unexpected therapeutic drug effect in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Concurrent medical conditions included rash.   On 02-MAR-2023, the patient received the 1st dose of Shingles vaccine. In MAR-2023, 2 days after receiving Shingles vaccine, the patient experienced unexpected therapeutic drug effect (Verbatim: Rash was going away). The outcome of the unexpected therapeutic drug effect was unknown.   It was unknown if the reporter considered the unexpected therapeutic drug effect to be related to Shingles vaccine.     It was unknown if the company considered the unexpected therapeutic drug effect to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 05-MAR-2023 This case was reported by a patient via interactive digital media. The patient got the first shot and the rash was going away already. He/she was never diagnosed for shingles, but it seemed to be helping anyway only 2 days later. Follow-up would not possible as no contact details were available.
Initial report received on 27 December 2008, from a physician, as part of a study for which is not a sponsor. A 38-year-old pregnant female experienced "A2" gestational diabetes after receiving on 04 May 2006 a first intramuscular, left deltoid injection of ADACEL. The patient began her current pregnancy as a twin pregnancy, and complications of pregnancy at the time of vaccination, revealed twin A had already expired at 10 weeks gestation on 29 March 2006. The patient took PEPCID, and prenatal vitamins throughout the pregnancy, and VICODIN occasionally throughout the pregnancy. The patient took Glyburide from 20 August 2006 to 20 October 2006, for gestation diabetes type A2. The patient's past obstetric history included two previous pregnancies that resulted in one live birth with no congenital anomalies and one spontaneous abortion prior to 20 weeks gestation. At the time of vaccination, the patient had current medical history of Body Mass Index of 29, past history of exercise induced asthma, history of malignant melanoma, right shoulder (1993) that was removed by wide local excision, a hiatal hernia causing gastroesophageal reflux disease, cholecystectomy (1999), motor vehicle accident (1990), resulting in compression fracture L2 vertebrae, and spondylolisthesis L5-S1, causing severe chronic low back and hip pain. The patient has no history of alcohol use, drug use, or tobacco use. Regarding the current pregnancy, the date of the patient's last menstrual period was on 17 January 2006, with an expected date of delivery on 27 October 2006. The patient had serology testing on 23 May 2005 and 05 September 2005, that were normal with O+, Rubella Imm, HIV Neg, RPR-NR, HGsAG-NR, and Gc/chlam-Neg/neg. A fetal stress test on 11 September 2006, started bi-weekly, non-stress testing at 34 weeks for A2 gestational diabetes. Eleven more fetal stress tests were performed from 11 September 2006 to 19 October 2006, that were normal. An ultrasound on 27 February 2006, revealed twin gestation; and ultrasound on 06 March 2006, revealed lagging growth of twin A; an ultrasound on 29 March 2006, revealed demise of twin A. Subsequently, three ultrasounds were performed from 24 May 2006 to 20 October 2006, that showed normal morphology and growth of twin B, and normal amniotic fluid index. The patient experienced complication of labor and was induced at 40+ weeks of gestation for gestational diabetes Mellitus Type A2. The patient delivered one live female baby via vaginal delivery at 40+ weeks. The baby's Apgar score were six at one minute, and nine at five minutes. The birth weight was 3290g (3 kilogram); and the baby did not suffer any congenital anomalies. At the time of the report, the patient was considered to be recovered. Documents held by sender: None. The reporter for this case is the same as in case numbers: 2008-04101, 2008-04102,2008-04103, 2008-04104, 2008-04105, 2008-04106, 2008-04107, 2008-04108, 2008-04109, 2008-04111, 2008-04112, 2008-04113, 2008-04114, 2008-04115, and 2008-04116.
had a period after menopause (last one 4 years prior).  Period lasted 5 days.; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2 (Pfizer-BioNTech COVID-19), on 02Apr2022 at 10:00 as dose 4 (booster), single (Lot number: RJ9943) at the age of 58 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Covid-19" (unspecified if ongoing), notes: if covid prior vaccination :Yes. Since the vaccination, the patient had not been tested for COVID-19. There were no concomitant medications in two weeks. Past drug history included: Keflex, reaction(s): "known allergies: Keflex". Vaccination history included: BNT162b2 (dose 1, lot number: ER5733, administration time=11:00AM, vaccine location=Right arm), administration date: 30Mar2021, when the patient was 57-year-old, for COVID-19 immunization; BNT162b2 (dose 2, lot number:EW0151, administration time: 10:00AM, vaccine location: Right arm), administration date: 27Apr2021, when the patient was 57-year-old, for COVID-19 Immunization; BNT162b2 (dose 3, lot number: FP2593, administration time: 10:00AM, vaccine location: Right arm), administration date: 23Oct2021, when the patient was 58-year-old, for Covid-19 immunization. The patient had not received any other vaccine within 4 weeks. The following information was reported: POSTMENOPAUSAL HAEMORRHAGE (medically significant) with onset 18Apr2022 at 03:00, outcome "unknown", described as "had a period after menopause (last one 4 years prior).  Period lasted 5 days.". The event "had a period after menopause (last one 4 years prior).  period lasted 5 days." required physician office visit. Therapeutic measures were not taken as a result of postmenopausal haemorrhage.  No follow-up attempts are possible. No further information is expected.
Left infraclavicular and supraclavicular lymphadenopathy, severe myalgias, local injection site swelling and pain. Patient was diagnosed with COVID-19 on September 28, 2020 and was 87 days after diagnosis at the time of vaccine.
Pt recvd vax & approx 24 hrs p/vax exp redness, soreness, heat @ site lasting several days; Did not receive treatment;
12 days p/vax unilateral rt parotid gland swelling, h/a, pain in rt face then devel arthralgia, then better;
8 hours after receiving the vaccine listed pt developed seizures and a low grade fever was noted. Duration of episode was reported by parent as being 2-3 minutes followed by 20 min of unarousability followed by normal but somewhat tired behavior.
Right deltoid area swollen, warm and tender. It is indurated and faintly erythematous too. Swelling local warmth and induration covers the upper 2/3 of lateral aspect of right upper arm. Treatment: Levaquin 250 mg 20x7 days, Benadryl
Positive for COVID.  Patient states they are vaccinated date unknown so 01/01/2021 put in  as placeholder
Itchy; Then it was raised; her injection site started to become red; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itchy), VACCINATION SITE MASS (Then it was raised) and INJECTION SITE ERYTHEMA (her injection site started to become red) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 14-Apr-2021, the patient experienced PRURITUS (Itchy), VACCINATION SITE MASS (Then it was raised) and INJECTION SITE ERYTHEMA (her injection site started to become red). At the time of the report, PRURITUS (Itchy), VACCINATION SITE MASS (Then it was raised) and INJECTION SITE ERYTHEMA (her injection site started to become red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No information provided about any treatment and concomitant medications.   Reporter did not allow further contact
Swelling from shoulder to elbow, redness and heat, slight rash. Soreness. Symptoms lasted 7 days then resolved.
employee came with for her to receive her 2nd dose of her hepatitis B, but i had accidentally gave her the peds vaccine instead of the adult one. Patient did not feel any symptoms.
Feeling chills all day; This spontaneous case was reported by an other and describes the occurrence of CHILLS (Feeling chills all day) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage form. On 30-Jan-2021, the patient experienced CHILLS (Feeling chills all day). At the time of the report, CHILLS (Feeling chills all day) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Spoke to mother at 3am, 8/11/03. She stated patienthad rash and hives 8/7/03, eyes swollen - called Dr, no resp. distress - patient improving.
Woke at 3:30am shaking, kept switching from freezing to sweating, achey, fidgety, nauseous, unable to sleep, headache, temperature over 102.
This initial non-serious spontaneous case, was received on 11-Sep-2017, from a pharmacy and concerns a 58-year-old adult female patient. The current condition of the patient was high cholesterol. The concomitant medications included atorvastatin for high cholesterol and MOTRIN. On 08-Sep-2017, the patient was administered with AFLURIA (TIV) (dose: 0.5 ml, expiry date: Jun-2018, route of administration, anatomical location, batch number: not reported). On 09-Sep-2017, the patient woke up with a stiff neck, but had no pain or swelling at the injection site. The patient notified about it to the pharmacist on 10-Sep-2017. The pharmacist spoke with the patient and suggested to consult a physician. As instructed by the physician, the patient took MOTRIN. At the time of this report, the patient recovered from the event. The causality between the event and the flu vaccine was not reported. Follow-up report received on 14-Sep-2017: Concomitant medications were updated. Outcome of the event was updated from not recovered to recovered.
Sudden onset sensorineural hearing loss with vertigo and tinnitus. No sense of balance
Patient was given Moderna 1 ml instead of 0.5 ml on 7/12/2021. Outcome: Patient experienced a fever on 7/13/2021, took Tylenol, symptoms resolved. No other symptoms, no need for ER visit.
was unaware that there was a 2nd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (In 2021, received first dose).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: was unaware that there was a 2nd dose). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 30-SEP-2023 The reporter had a patient who received the first dose of the shingles vaccine back in 2021 and was unaware that there was a 2nd dose.  The reporter understood that they were supposed to administer the 2nd dose as soon as possible but, since it was over 2 years ago, she did not know if they needed to restart the series or not. No further details provided on web form. The reporter consented to follow up. Till the time of reporting, the patient did not receive the second dose of Shingrix, which led to incomplete course of vaccination.